A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(12 sites)

United States

Winship Cancer Institute, Atlanta, Georgia

University of Maryland School of Medicine, Baltimore, Maryland

Washington University School of Medicine, St Louis, Missouri

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Germany

Universitätsklinikum Köln (AöR), Cologne

Technische Universität Dresden, Dresden

Universitätsklinikum Würzburg AÖR, Würzburg

Japan

National Cancer Center Hospital East, Chiba, Kashiwa

Spain

Hospital del Mar, Barcelona

Hospital Universitari Vall D Hebron, Barcelona

Clínica Universidad de Navarra, Pamplona

Hospital Clinico Universitario De Valencia, Valencia